OTC · Drug Manufacturers - Specialty & Generic

H. Lundbeck A/S (HLBBF) Stock

$6.60 +0.00% OTC: HLBBF Healthcare

H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales.

Valuation

MetricValue
Price$6.60
Market Cap$5.23B
P/E Ratio11.50
P/B Ratio1.66
P/S Ratio1.35
EPS (TTM)$0.57
52-Week High$7.55
52-Week Low$5.15
Dividend Yield2.73%

Financials & Margins

MetricValue
ROE14.81%
ROA7.07%
ROCE16.17%
Gross Margin78.95%
Operating Margin27.86%
Net Margin14.71%
Debt/Equity0.43
Current Ratio1.41

Annual Financials (USD)

Metric20212022202320242025
Revenue$16.3B$18.2B$19.9B$22.0B$24.3B
Operating Profit$2.0B$2.9B$3.2B$3.3B$6.3B
Net Profit$1.3B$1.9B$2.3B$3.1B$3.2B
EPS$1.33$1.93$2.31$3.17$3.21
Op Margin12.3%15.6%16.1%14.9%26.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$34.7B$37.5B$37.4B$57.0B$53.9B
Total Liabilities$16.4B$16.7B$15.4B$32.0B$29.0B
Cash$2.3B$3.4B$5.0B$4.7B$3.4B
Borrowings$5.3B$5.6B$4.2B$16.7B$11.7B

Latest News

Update: Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition MT Newswires · Sep 30, 2026 Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports Investing.com · Sep 29, 2026 Sector Update: Healthcare Stocks Decline Tuesday Afternoon MT Newswires · Sep 29, 2026 Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition MT Newswires · Sep 29, 2026 Can H. Lundbeck (CPSE:HLUN B) Look Cheap On Japan Eptinezumab Approval? Simply Wall St. · Sep 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$2.3B$3.5B$4.1B$3.3B$4.9B
Investing Cash Flow$-1.4B$-2.7B$-999.0M$-15.9B$-1.2B
Financing Cash Flow$-116.0M$-138.0M$-132.0M$-135.0M$488.0M
Net Cash Flow$-1.6B$1.3B$1.5B$-346.0M$-680.0M
Free Cash Flow$1.7B$2.7B$3.6B$2.8B$4.3B

Valuation & Return Ratios

MetricValue
PEG Ratio0.95
EV / EBITDA5.51
FCF Yield12.68%
Quick Ratio0.90
Interest Coverage11.75
Return 1Y9.01%
Return 3Y48.39%
Return 5Y—

Ownership

Insiders Held0.10%
Institutions Held80.12%
Institutions Float Held80.20%
Institutional HolderSharesReport Date
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund3,695,1532026-04-30
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.3,282,2502026-04-30
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund2,898,6122026-03-31
iShares Trust-iShares Core MSCI EAFE ETF1,943,5412026-06-30
DFA INVESTMENT TRUST CO-The Continental Small Company Series1,500,6522026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
STENO.COStenocare A/S $0.92 -2.13% -45.50 $38.88M 0.00%

About H. Lundbeck A/S

H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily specializes in therapeutic solutions for psychiatric and neurological disorders across Europe, North America, and other worldwide regions. Among its prominent offerings are Abilify Maintena and Rexulti/Rxulti, prescribed for schizophrenia; Brintellix/Trintellix and Rexulti/Rxulti for the management of depression; Vyepti for the prevention of migraine attacks; and Northera, used to treat symptomatic neurogenic orthostatic hypotension. Lundbeck's diverse product lineup further includes Azilect for Parkinson's disease, Cipralex/Lexapro for depression, Ebixa for Alzheimer's disease, Onfi for Lennox-Gastaut syndrome, Sabril for epilepsy, and Xenazine for chorea associated with Huntington's disease, among others. The company's pharmaceuticals are primarily distributed to pharmaceutical wholesalers, retail pharmacies, and healthcare facilities like hospitals. Demonstrating a commitment to innovation and evidence-based medicine, Lundbeck has forged strategic alliances, including an agreement with Verantos to gather real-world evidence supporting migraine therapies, and a partnership with Rgenta Therapeutics, Inc. Founded in 1915, H. Lundbeck A/S maintains its corporate headquarters in Valby, Denmark.

H. Lundbeck A/S is headquartered in DK.

H. Lundbeck A/S (HLBBF) stock trades at $6.60 with a market capitalization of $5.23B. The stock is valued at a price-to-earnings (P/E) ratio of 11.50, price-to-book of 1.66, price-to-sales of 1.35. Over the past 52 weeks the stock has ranged between $5.15 and $7.55, and currently trades 12.6% below its 52-week high. It pays a dividend yielding 2.73%.

On profitability, H. Lundbeck A/S generates a return on equity (ROE) of 14.81%, above the typical market average, return on capital employed of 16.17%, an operating margin of 27.86%, a net profit margin of 14.71%.

Official website: www.lundbeck.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides